QuickView for Omeprazole (compound)

Summary
General Info

PubChem

PubChem Compound 130564

Name:	Omeprazole
PubChem Compound ID:	130564
Description:	A highly effective inhibitor of gastric acid secretion used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-EXCHANGING ATPASE) in the proton pump of GASTRIC PARIETAL CELLS.
Molecular formula:	C₃₄H₃₆MgN₆O₆S₂
Molecular weight:	713.123 g/mol
Synonyms:	(-)-Omeprazole magnesium; Nexium; Prilosec OTC; Esomeprazole magnesium [USAN:INN]; 320416-93-1; 95382-33-5; 202742-32-3; 161973-10-0; H 199/18; D05259. show more » (-)-Omeprazole magnesium; Nexium; Prilosec OTC; Esomeprazole magnesium [USAN:INN]; 320416-93-1; 95382-33-5; 202742-32-3; 161973-10-0; H 199/18; D05259; 371759-50-1; Magnesium, bis(5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl-kappaO)-1H-benzimidazolato-kappaN1)-, (T-4)-; (S)-Omeprazole magnesium; 372519-57-8; Esomeprazole magnesium; 376628-34-1; Magnesium, bis(5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazolato)-, (T-4-(S),(S))-; Perprazole; Prilosec OTC (TN); Omeprazole magnesium (USAN); 302841-07-2; Omeprazole magnesium show less «

DrugBank

Identification

Name:	Omeprazole
Name (isomeric):	DB00338
Drug Type:	small molecule
Description:	A highly effective inhibitor of gastric acid secretion used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-EXCHANGING ATPASE) in the proton pump of GASTRIC PARIETAL CELLS.
Synonyms:	OMP; Omeprazol [INN-Spanish]; Omeprazolum [INN-Latin]; OMEP; OMZ; Omeprazole magnesium
Brand:	Gasec, Pepticum, Ulcozol, Gastrimut, Danlox, Omid, Omesek, Exter, Aulcer, Inhibitron, Omed, Omeprol, Zefxon, Ocid, Audazol, Miracid, Zegerid, Belmazol, Emeproton, Ulsen, Pepticus, Antra, Prazidec, Mepral, Omebeta 20, Omezolan, Demeprazol, Olexin, Ramezol, Morecon, Regulacid, Prazolit, Result, Erbolin, Nilsec, Ulcometion, Paprazol, Dizprazol, Omisec, Gastroloc, Lomac, Logastric, Omeprazon, Ozoken, Prazentol, Losec, Ultop, Secrepina, Procelac, Ulcsep, Ceprandal, Prysma, Parizac, Miol, Indurgan, Elgam, Omapren, Omegast, Lensor, Inhipump, Victrix, Ulzol, Zepral, Gibancer, Zoltum, Sanamidol, Osiren, Mopral, Omizac, Peptilcer, Desec, Ompanyt, Proclor, Prilosec, Zimor, Ulcesep, Nopramin, Tedec Ulceral, Epirazole, Ortanol, Omezol, Omepral, Dudencer, Ulceral
Category:	Anti-Ulcer Agents, Enzyme Inhibitors, Proton-pump Inhibitors
CAS number:	73590-58-6

Pharmacology

Indication:	For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Pharmacology:	Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles,... show more » Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H⁺/K⁺ ATPase at the secretory surface of the gastric parietal cell. As a result, it inhibits acid secretion into the gastric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. show less «
Mechanism of Action:	Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H⁺/K⁺-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.
Absorption:	Absorption is rapid, absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg.
Protein binding:	95%
Biotransformation:	Hepatic.
Route of elimination:	Urinary excretion is a primary route of excretion of omeprazole metabolites.
Half Life:	0.5-1 hour
Clearance:	total body cl=500-600 mL/min [healthy] 250 mL/min [Geriatric] 70 mL/min [Hepatic Impairment] 10 - 62 mL/min/1.73 m2 [Renal Impairment]
Toxicity:	Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Avoid alcohol.

Take 30-60 minutes before meals.

Drug interaction:

Fosphenytoin	Omeprazole increases the effect of hydantoin
Phenytoin	Omeprazole increases the effect of hydantoin
Atazanavir	This gastric pH modifier decreases the levels/effects of atazanavir
Ethotoin	Omeprazole increases the effect of hydantoin
Trimipramine	The strong CYP2C19 inhibitor, Omeprazole, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Omeprazole is initiated, discontinued or dose changed.

Fosphenytoin	Omeprazole increases the effect of hydantoin
Phenytoin	Omeprazole increases the effect of hydantoin
Atazanavir	This gastric pH modifier decreases the levels/effects of atazanavir
Ethotoin	Omeprazole increases the effect of hydantoin
Trimipramine	The strong CYP2C19 inhibitor, Omeprazole, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Omeprazole is initiated, discontinued or dose changed.
Itraconazole	The proton pump inhibitor, omeprazole, may decrease the absorption of itraconazole.
Triazolam	Omeprazole may increase the effect of the benzodiazepine, triazolam.
Enoxacin	Omeprazole may decrease the absorption of enoxacin.
Methotrexate	Omeprazole increases the levels of methotrexate
Ketazolam	Omeprazole may increase the effect of the benzodiazepine, ketazolam.
Clorazepate	Omeprazole may increase the effect of the benzodiazepine, clorazepate.
Indinavir	Omeprazole decreases the absorption of indinavir
Halazepam	Omeprazole may increase the effect of the benzodiazepine, halazepam.
Estazolam	Omeprazole may increase the effect of the benzodiazepine, estazolam.
Clonazepam	Omeprazole may increase the effect of the benzodiazepine, clonazepam.
Voriconazole	Voriconazole increases the effect and toxicity of omeprazole
Chlordiazepoxide	Omeprazole may increase the effect of the benzodiazepine, chlordiazepoxide.
Disopyramide	The beta-blocker increases toxicity of disopyramide
Tipranavir	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Omeprazole. Consider alternate therapy or increase the dose of Omeprazole based on the therapeutic response.
Midazolam	Omeprazole may increase the effect of the benzodiazepine, midazolam.
Prazepam	Omeprazole may increase the effect of the benzodiazepine, prazepam.
Cyclosporine	Omeprazole increases the effect and toxicity of cyclosporine
Cilostazol	Omeprazole increases the effect of cilostazol
Flurazepam	Omeprazole may increase the effect of the benzodiazepine, flurazepam.
Diazepam	Omeprazole may increase the effect of the benzodiazepine, diazepam.
Cefditoren	Proton pump inhibitors such as omeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
St. John's Wort	St. John's Wort decreases the levels/effects of omeprazole
Tacrolimus	Omeprazole may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Omeprazole therapy is initiated, discontinued or altered.
Mephenytoin	Omeprazole increases the effect of hydantoin
Clopidogrel	Omeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Clopidogrel prescribing information recommends avoiding concurrent use with omeprazole, due to the possibility that combined use may result in decreased clopidogrel effectiveness.
Ketoconazole	The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole.
Quazepam	Omeprazole may increase the effect of the benzodiazepine, quazepam.
Alprazolam	Omeprazole may increase the effect of the benzodiazepine, alprazolam.
Dasatinib	Omeprazole may decrease the serum level of dasatinib.

show less «

Targets

Potassium-transporting ATPase alpha chain 1

Enzymes

Cholesterol side-chain cleavage enzyme, mitochondrial

Cytochrome P450 1A1

Cytochrome P450 1B1

Transporters

Canalicular multispecific organic anion transporter 2

Multidrug resistance protein 1

ATP-binding cassette sub-family G member 2